Pulmonx Corporation (LUNG)
- Previous Close
8.77 - Open
8.87 - Bid 8.87 x 500
- Ask 8.94 x 100
- Day's Range
8.73 - 9.20 - 52 Week Range
7.11 - 14.84 - Volume
187,201 - Avg. Volume
635,354 - Market Cap (intraday)
345.849M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-1.54 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.40
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
pulmonx.comRecent News: LUNG
Performance Overview: LUNG
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LUNG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LUNG
Valuation Measures
Market Cap
345.85M
Enterprise Value
270.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.67
Price/Book (mrq)
3.13
Enterprise Value/Revenue
3.70
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-80.46%
Return on Assets (ttm)
-20.52%
Return on Equity (ttm)
-46.17%
Revenue (ttm)
72.99M
Net Income Avi to Common (ttm)
-58.73M
Diluted EPS (ttm)
-1.54
Balance Sheet and Cash Flow
Total Cash (mrq)
116.13M
Total Debt/Equity (mrq)
36.72%
Levered Free Cash Flow (ttm)
-19.89M
Research Analysis: LUNG
Company Insights: LUNG
LUNG does not have Company Insights